Tuesday, June 11, 2019
Not Much Fizz in LaCroix Right Now

Wednesday, May 29, 2019
An Example of Calcbench, Excel, and Insight

Monday, May 20, 2019
Research Paper: Capex Spending

Thursday, May 16, 2019
Psst: Got Any Weed?

Wednesday, May 15, 2019
Open Letter: SEC Proposed Rule for BDCs

Friday, May 10, 2019
General Motors and Workhorse

Monday, May 6, 2019
How to Find Earnings Release Data

Tuesday, April 23, 2019
Following Restructuring Costs Over Time

Monday, April 22, 2019
Capex Spending: More Than You Might Think

Saturday, April 13, 2019
When AWS Takes Over the World

Thursday, April 11, 2019
Data Trends in Focus: Restructuring Costs

Sunday, April 7, 2019
How One Customer Crushed It With Calcbench

Thursday, April 4, 2019
TJX Shows Complexity of Leasing Costs Reporting

Tuesday, April 2, 2019
CEO Pay Ratios: Some 2018 Thoughts

Wednesday, March 27, 2019
Corporate Spending: Where It Goes, 2017 vs. 2018

Monday, March 25, 2019
Health Insurers: A Bit Winded?

Friday, March 22, 2019
Our New Master Class Video

Thursday, March 21, 2019
Tech Data’s Goodwill Adjustment

Tuesday, March 19, 2019
There’s Taxes, and There’s Taxes

Saturday, March 16, 2019
Adventures in Tax Cuts and Net Income

Archive  |  Search:

In the discussion about HR 4164 we’ve heard a lot about the ‘hardships’ faced by the ‘small, development stage companies’ who are ‘struggling’ to meet their XBRL requirement.

First of all, it’s our opinion that the benefits of being publically listed are equally great whether you are large or small, and therefore size should not be an factor in your reporting requirement.

But putting that aside for a moment, let’s take a look at just one of these “emerging growth” companies that would be exempted, if in fact a limit of $250 million in revenue were enacted.

Introducing Isis Pharmaceuticals (Nasdaq: ISIS)
Publicly traded for: 23 years
Market cap: $5.4 BILLION
Only 147.3 million in revenue in 2013
BUT $847 MILLION in assets
AND 656.8 MILLION in cash and short term investments

Does any of this sound like ‘emerging growth?’

But there’s more:

Isis raised $173.3 MILLION in the last year alone by issuing new stock on Nasdaq. In order to do that they happily paid $9.5 MILLION in fees to investment banks.

AND yet a few thousand a year to report financials back to those same generous investors in a much more efficient, machine readable format is too much to ask?

Clearly, it doesn’t add up!

Incidentally, this research took a grand total of 5 minutes because of, you guessed it, the magic of XBRL.

FREE Calcbench Premium
Two Week Trial

Research Financial & Accounting Data Like Never Before. More features and try our Excel add-in. Sign up now to try the Premium Suite.